ArticleFrontiers in oncology2022

Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study.

Riccardo Marconcini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.